Literature DB >> 31499048

No prevention or cure of epilepsy as yet.

Pavel Klein1, Ivana Tyrlikova2.   

Abstract

Approximately 20% of all epilepsy is caused by acute acquired injury such as traumatic brain injury, stroke and CNS infection. The known onset of the injury which triggers the epileptogenic process, early presentation to medical care, and a latency between the injury and the development of clinical epilepsy present an opportunity to intervene with treatment to prevent epilepsy. No such treatment exists and yet there has been remarkably little clinical research during the last 20 years to try to develop such treatment. We review possible reasons for this, possible ways to rectify the situations and note some of the ways currently under way to do so. Resective surgical treatment can achieve "cure" in some patients but is sparsely utilized. In certain "self-limiting" syndromes of childhood and adolescence epilepsy remits spontaneously. In a proportion of patients who become seizure free on medications or with dietary treatment, seizure freedom persists when treatment is discontinued. We discuss these situations which can be considered "cures"; and note that at present we have little understanding of mechanism of such cures, and cannot therefore translate them into a treatment paradigm targeting a "cure" of epilepsy. This article is part of the special issue entitled 'New Epilepsy Therapies for the 21st Century - From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy'.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiseizure drugs; Biomarkers; Cerebrovascular accident; Epilepsy; Epilepsy cure; Epilepsy prevention; Epilepsy surgery; Epileptogenesis; Post-stroke epilepsy; Post-traumatic epilepsy; Traumatic brain injury

Mesh:

Substances:

Year:  2019        PMID: 31499048     DOI: 10.1016/j.neuropharm.2019.107762

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  9 in total

Review 1.  Impact of predictive, preventive and precision medicine strategies in epilepsy.

Authors:  Rima Nabbout; Mathieu Kuchenbuch
Journal:  Nat Rev Neurol       Date:  2020-10-19       Impact factor: 42.937

Review 2.  Identification of clinically relevant biomarkers of epileptogenesis - a strategic roadmap.

Authors:  Michele Simonato; Denes V Agoston; Amy Brooks-Kayal; Chris Dulla; Brandy Fureman; David C Henshall; Asla Pitkänen; William H Theodore; Roy E Twyman; Firas H Kobeissy; Kevin K Wang; Vicky Whittemore; Karen S Wilcox
Journal:  Nat Rev Neurol       Date:  2021-02-16       Impact factor: 42.937

3.  In-depth characterization of a mouse model of post-traumatic epilepsy for biomarker and drug discovery.

Authors:  Rossella Di Sapia; Federico Moro; Marica Montanarella; Valentina Iori; Edoardo Micotti; Daniele Tolomeo; Kevin K W Wang; Annamaria Vezzani; Teresa Ravizza; Elisa R Zanier
Journal:  Acta Neuropathol Commun       Date:  2021-04-26       Impact factor: 7.801

Review 4.  Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: Opportunities for novel therapeutics development.

Authors:  Jennifer Leigh Green; Wagner Ferreira Dos Santos; Andréia Cristina Karklin Fontana
Journal:  Biochem Pharmacol       Date:  2021-09-24       Impact factor: 5.858

Review 5.  Viral infections and their relationship to neurological disorders.

Authors:  Jéssica Wouk; Daniele Zendrini Rechenchoski; Bianca Cerqueira Dias Rodrigues; Elisa Vicente Ribelato; Ligia Carla Faccin-Galhardi
Journal:  Arch Virol       Date:  2021-01-27       Impact factor: 2.574

6.  MTEP, a Selective mGluR5 Antagonist, Had a Neuroprotective Effect but Did Not Prevent the Development of Spontaneous Recurrent Seizures and Behavioral Comorbidities in the Rat Lithium-Pilocarpine Model of Epilepsy.

Authors:  Alexandra V Dyomina; Anna A Kovalenko; Maria V Zakharova; Tatiana Yu Postnikova; Alexandra V Griflyuk; Ilya V Smolensky; Irina V Antonova; Aleksey V Zaitsev
Journal:  Int J Mol Sci       Date:  2022-01-02       Impact factor: 5.923

7.  Gout and the risk of epilepsy: A population-based cohort study.

Authors:  Hung-Lin Chen; Yi-Chao Hsu; Chang-Hsu Chen; Pei-Jen Wang; Cheng-Li Lin; Sheng-Han Cheng; Kuang-Hsi Chang
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

Review 8.  The Role of Cyclodextrins in the Design and Development of Triterpene-Based Therapeutic Agents.

Authors:  Alexandra Prodea; Alexandra Mioc; Christian Banciu; Cristina Trandafirescu; Andreea Milan; Roxana Racoviceanu; Roxana Ghiulai; Marius Mioc; Codruta Soica
Journal:  Int J Mol Sci       Date:  2022-01-10       Impact factor: 5.923

Review 9.  The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.

Authors:  Wolfgang Löscher; Pavel Klein
Journal:  CNS Drugs       Date:  2021-06-18       Impact factor: 5.749

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.